Last updated: September 9, 2026
Insulin detemir, marketed by Novo Nordisk as Levemir, has moved from a major basal-insulin product to a declining, largely legacy franchise. Global sales fell from about DKK 7.8 billion in 2021 to DKK 4.0 billion in 2023. Novo Nordisk discontinued Levemir in the United States by the end of 2024, citing declining demand and manufacturing constraints. The commercial opportunity has shifted from branded growth to replacement demand, supply continuity, and potential follow-on insulin development.
What is the market status of insulin detemir?
Insulin detemir is a long-acting recombinant human insulin analog. Novo Nordisk designed it for once- or twice-daily basal glycemic control, with albumin binding contributing to its prolonged duration of action.
| Product |
Active ingredient |
Sponsor |
FDA status |
Primary use |
| Levemir |
Insulin detemir |
Novo Nordisk |
Approved under NDA 021536 |
Basal insulin for diabetes |
| Lantus, Toujeo |
Insulin glargine |
Sanofi |
Approved |
Basal insulin |
| Basaglar, Semglee, Rezvoglar |
Insulin glargine |
Eli Lilly, Viatris/Biocon, Eli Lilly |
Approved follow-on or biosimilar products |
Basal insulin |
| Tresiba |
Insulin degludec |
Novo Nordisk |
Approved |
Ultra-long-acting basal insulin |
| NPH insulin |
Human insulin isophane |
Multiple companies |
Approved |
Intermediate-acting basal insulin |
Levemir’s original differentiation was its predictable basal profile and lower weight-gain perception relative to some older insulin regimens. That differentiation weakened as insulin glargine expanded, insulin degludec gained adoption, and payers prioritized lower-cost basal insulin options.
When did insulin detemir lose exclusivity?
Insulin detemir’s principal market protection has expired or ceased to be commercially meaningful in the United States. The product no longer has a material patent-based barrier that protects premium pricing.
The relevant exclusivity structure included:
| Protection category |
Insulin detemir position |
| FDA approval |
Levemir received U.S. approval in 2005 |
| New chemical entity exclusivity |
Expired years ago |
| Primary composition and formulation patents |
Expired or no longer commercially decisive |
| Orange Book protection |
No active patent barrier is generally understood to prevent follow-on competition |
| Regulatory pathway |
Follow-on insulin can be developed under the biologics framework |
| Commercial protection |
Previously supported by manufacturing complexity, physician familiarity, and payer contracts |
Insulin products are biologics under the Public Health Service Act. Since March 2020, insulin products have been regulated under the biologics framework rather than the former drug framework, allowing sponsors to pursue biosimilar or interchangeable-biologic pathways under section 351(k) of the Public Health Service Act. The statutory transition did not restore meaningful exclusivity to Levemir.
What patents protect insulin detemir?
The commercially important patent estate for insulin detemir was built around insulin analog chemistry, formulations, manufacturing, and therapeutic use. The core estate has aged beyond the period when it could support a durable U.S. monopoly.
The principal barriers to competition are now technical rather than patent-based:
- Protein sequence and impurity control
- Consistent biological activity
- Formulation stability
- Delivery-device compatibility
- Batch-to-batch comparability
- Analytical characterization
- Regulatory requirements for insulin biosimilarity or interchangeability
- Manufacturing scale and supply reliability
A competitor therefore faces development and manufacturing costs, but not the type of active composition-of-matter barrier that protected Levemir during its growth period.
What is the financial trajectory of Levemir?
Levemir sales declined sharply before the U.S. discontinuation. Novo Nordisk’s reported product-sales data show a sustained erosion in revenue.
| Fiscal year |
Levemir sales, approximately |
Year-over-year direction |
| 2021 |
DKK 7.8 billion |
Declining |
| 2022 |
DKK 5.9 billion |
Declining |
| 2023 |
DKK 4.0 billion |
Declining |
| 2024 |
U.S. withdrawal and continued contraction |
Materially lower |
From 2021 to 2023, sales declined by approximately 48%. The decline reflected several forces:
- Substitution by insulin degludec and insulin glargine.
- Greater use of lower-priced follow-on insulin glargine products.
- Managed-care pressure on basal-insulin formularies.
- Reduced physician preference for twice-daily detemir in patients requiring stronger duration.
- Lower strategic priority within Novo Nordisk’s portfolio.
- Product discontinuation and supply-management actions in the United States.
Levemir represented a small and shrinking share of Novo Nordisk’s overall diabetes portfolio. Novo’s growth increasingly came from Ozempic, Rybelsus, Wegovy, Tresiba, and newer diabetes therapies rather than older basal insulin products.
Why did Novo Nordisk discontinue insulin detemir in the United States?
Novo Nordisk announced the discontinuation of Levemir in the U.S. market, with all formulations scheduled to be discontinued by the end of 2024. The company cited declining sales and manufacturing constraints. The company’s U.S. communications identified the withdrawal as a commercial and supply decision rather than a safety-driven regulatory recall.
The discontinuation affected:
- Levemir FlexTouch pens
- Levemir FlexPen products
- Levemir vials
- Associated prescribing and substitution patterns
Novo Nordisk directed clinicians toward alternative basal-insulin products, including Tresiba and other available basal insulins. The withdrawal reduced patient choice but also removed a low-growth product from Novo’s manufacturing network.
The U.S. discontinuation does not mean insulin detemir became medically obsolete. Patients who respond well to detemir may still require individualized conversion to insulin degludec, insulin glargine, NPH insulin, or another basal regimen.
What is the FDA regulatory status of insulin detemir?
Levemir was approved by the FDA under NDA 021536 for adults and children with diabetes. The product was approved for type 1 diabetes and type 2 diabetes indications, with dosing dependent on the patient’s treatment regimen and clinical response.
The regulatory position has three commercial implications:
- FDA approval established the reference-product record for potential biosimilar development.
- The product’s biologic transition allowed follow-on insulin development through the 351(k) pathway.
- Discontinuation reduces the commercial value of developing a U.S. Levemir biosimilar unless the sponsor targets markets where detemir remains available.
FDA withdrawal of a product from commercial distribution does not automatically eliminate the reference-product science or the possibility of regulatory reliance. It does, however, make market access, reference-product sourcing, and commercial positioning more difficult.
What is the Orange Book status of Levemir?
Levemir was originally approved as a drug product and was included in the FDA’s drug-regulatory framework before the 2020 insulin transition. Its historical patent and exclusivity position is no longer a meaningful commercial barrier.
The key distinction is between:
- Historical Orange Book-listed rights associated with the original NDA; and
- Current biologic competition under the Purple Book and section 351(k) framework.
Because insulin products moved into the biologics system, future follow-on competition is assessed primarily through biologic interchangeability and biosimilarity standards rather than the conventional small-molecule ANDA model.
A generic-drug Paragraph IV challenge is therefore not the central risk model for Levemir. A follow-on sponsor would more likely pursue a biosimilar or interchangeable biosimilar pathway, depending on the reference-product and market circumstances.
Are there Paragraph IV challenges to insulin detemir?
There is no major active Paragraph IV litigation program comparable to the litigation surrounding blockbuster small-molecule drugs. The relevant competitive pathway for modern insulin competition is biologic follow-on development rather than a conventional ANDA-based Paragraph IV launch.
A Paragraph IV-style challenge would have limited strategic value because:
- Core Levemir exclusivity has expired or lost practical significance.
- The product is being withdrawn in the United States.
- Basal-insulin competition already includes lower-cost glargine products.
- Commercial demand is shifting toward degludec, glargine, and lower-cost human insulin.
- A new entrant would need to justify investment in a declining reference-product market.
Is there a biosimilar or interchangeable insulin detemir product?
As of the public regulatory landscape through 2024, no major FDA-approved biosimilar or interchangeable insulin detemir product had established a meaningful U.S. market position.
The absence of a detemir biosimilar is commercially rational. Sponsors have stronger incentives to develop insulin glargine because:
- Glargine has a larger installed patient base.
- The reference product remains commercially active.
- Several follow-on products have already created a defined regulatory and payer market.
- Glargine has stronger formulary relevance.
- Manufacturing and development costs can be spread across a larger addressable market.
The U.S. approval of Semglee as an interchangeable biosimilar to Lantus demonstrated that insulin analogs can support a substitution-oriented commercial model. That precedent benefits the broader follow-on insulin sector, but it does not create a direct commercial opportunity for detemir.
How does insulin detemir compare with insulin glargine and insulin degludec?
| Attribute |
Insulin detemir |
Insulin glargine |
Insulin degludec |
| Main brand |
Levemir |
Lantus, Toujeo |
Tresiba |
| Sponsor originator |
Novo Nordisk |
Sanofi |
Novo Nordisk |
| Duration profile |
Long-acting, often once or twice daily |
Long-acting, formulation-dependent |
Ultra-long-acting |
| Follow-on competition |
Limited |
Extensive |
Limited relative to glargine |
| U.S. commercial status |
Discontinued by end of 2024 |
Active |
Active |
| Payer pressure |
High |
Very high |
Increasing |
| Strategic trajectory |
Declining and withdrawn |
Large, competitive market |
Growth and replacement product |
| Manufacturing value |
Low as a branded franchise |
High because of market scale |
High within Novo’s portfolio |
Detemir’s competitive weakness was not solely its price. It also faced a duration disadvantage in some patients. Degludec offers a longer and more flexible basal profile, while glargine has broad clinical familiarity and a deep follow-on market.
What generic entry risks exist for insulin detemir?
The generic-entry risk for Levemir is low in the traditional sense because the originator is already exiting the U.S. market. The higher risk is substitution by competing basal insulins.
Direct follow-on risk
A detemir biosimilar could technically compete in markets where Levemir remains available. Its prospects would depend on:
- Reference-product availability
- Reimbursement pricing
- Physician demand
- Device compatibility
- International tender access
- Clinical conversion requirements
- Manufacturing cost
Indirect substitution risk
Indirect competition is stronger. A patient leaving Levemir may be moved to:
- Insulin degludec
- Insulin glargine U-100
- Insulin glargine U-300
- NPH insulin
- Other basal regimens determined by payer coverage
The substitution market is therefore larger than the potential detemir follow-on market.
What patent and manufacturing barriers remain?
The key manufacturing barrier is the ability to produce a highly consistent recombinant insulin analog at commercial scale. Detemir is a complex biologic product, even though its molecular structure is well characterized.
A credible competitor would need:
- Recombinant expression and purification capability
- Validated control of impurities and aggregates
- Potency and identity assays
- Stability data
- Drug-device combination testing for pen presentations
- Good Manufacturing Practice capacity
- Pharmacokinetic and pharmacodynamic comparability data
- A validated global supply chain
The manufacturing burden favors established insulin producers such as Eli Lilly, Sanofi, Biocon, Viatris, Wockhardt, and regional insulin manufacturers. It is less favorable for small biotechnology companies without protein-manufacturing infrastructure.
Which companies are challenging the basal-insulin market?
The main competitive companies are:
| Company |
Relevant basal-insulin position |
| Novo Nordisk |
Tresiba and legacy Levemir franchise |
| Sanofi |
Lantus and Toujeo |
| Eli Lilly |
Basaglar, Rezvoglar, and insulin products |
| Viatris/Biocon Biologics |
Semglee and biosimilar insulin glargine |
| Wockhardt |
Human insulin and regional insulin products |
| Ypsomed and device partners |
Delivery-device and insulin-delivery participation rather than originator detemir competition |
The commercial contest is concentrated around price, formulary access, delivery devices, supply reliability, and dosing convenience. Detemir is no longer a central growth asset in that contest.
What licensing deals affect insulin detemir?
No major recent licensing transaction has materially changed the commercial outlook for insulin detemir. Licensing activity in insulin has focused more heavily on:
- Biosimilar insulin glargine
- Human insulin supply
- Regional commercialization rights
- Pen and pump technologies
- Contract manufacturing
- Affordable-insulin initiatives
For detemir, a licensing deal would likely be economically justified only in selected international markets where the product remains clinically established and supply remains constrained. A global licensing transaction would face weak demand in the United States and intense substitution from glargine and degludec.
What is the geographic coverage of insulin detemir?
Levemir historically had broad international approval and commercial distribution. Its geographic value is now uneven.
| Region |
Commercial outlook |
| United States |
Discontinued by the end of 2024 |
| Europe |
Mature or declining product, with country-level availability varying |
| Japan |
Mature basal-insulin market with strong competitor presence |
| Emerging markets |
Potential residual demand, but price-sensitive |
| Tender markets |
Vulnerable to lower-cost human insulin and glargine |
| Low- and middle-income countries |
Access depends on procurement price and local supply |
The commercial opportunity is therefore regional rather than global. Remaining demand may persist in countries where physicians are familiar with detemir, reimbursement systems support it, or patients have stable control on the product.
What is the investment outlook for insulin detemir?
Insulin detemir has limited standalone investment appeal. Revenue is declining, the U.S. market has been withdrawn, and the product lacks a strong patent-based growth runway.
The principal value drivers are:
- Residual international sales
- Potential supply agreements
- Manufacturing-asset redeployment
- Patient conversion to Novo Nordisk’s newer basal-insulin products
- Portfolio simplification
- Reduced costs from exiting a low-growth franchise
For Novo Nordisk, the withdrawal can support margin and operational focus by shifting resources toward higher-growth products. For competitors, the opportunity is mainly to capture converted patients, not to build a large detemir-centered franchise.
Key Takeaways
- Levemir is a mature long-acting insulin analog with a declining commercial base.
- Global sales fell from approximately DKK 7.8 billion in 2021 to DKK 4.0 billion in 2023.
- Novo Nordisk discontinued U.S. Levemir sales by the end of 2024.
- Patent exclusivity is no longer the principal barrier to competition.
- Modern follow-on competition would use a biologic pathway rather than a conventional generic Paragraph IV strategy.
- No major FDA-approved insulin detemir biosimilar had established a U.S. market position through 2024.
- Insulin glargine and insulin degludec are the primary products capturing detemir demand.
- Remaining opportunity is concentrated in international markets, supply contracts, and patient-conversion products.
- The strongest investment thesis is portfolio replacement, not detemir revenue growth.
FAQs About Insulin Detemir Market and Patent Risk
Is insulin detemir still available in the United States?
Novo Nordisk discontinued Levemir products in the United States by the end of 2024. Patients generally require conversion to another basal insulin under clinical supervision.
Will a generic version of Levemir launch?
A conventional generic launch is unlikely to be the main competitive path. A follow-on sponsor would more likely pursue a biosimilar or interchangeable biologic, but the declining market reduces the commercial incentive.
Which insulin replaces Levemir most often?
Common alternatives include insulin degludec, insulin glargine, and NPH insulin. The appropriate replacement depends on dosing, glycemic control, insurance coverage, and patient-specific factors.
Did Novo Nordisk discontinue Levemir because of a safety issue?
The discontinuation was attributed to declining demand and manufacturing constraints, not a safety-driven withdrawal.
Is insulin detemir more profitable than insulin glargine?
No. Glargine has a substantially larger active market and established follow-on competition. Detemir’s revenue and strategic value declined materially before its U.S. withdrawal.
References
-
Food and Drug Administration. (2005). Levemir insulin detemir prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2020). Regulatory transition of insulin and other products under the Biologics Price Competition and Innovation Act. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
Novo Nordisk A/S. (2022). Annual report 2022. Bagsværd, Denmark.
-
Novo Nordisk A/S. (2023). Annual report 2023. Bagsværd, Denmark.
-
Novo Nordisk A/S. (2024). Levemir discontinuation and product availability communications. Bagsværd, Denmark.
-
U.S. Congress. (2010). Patient Protection and Affordable Care Act, section 7002: Biosimilar biological products. Washington, DC.
